| 中文名称: | 枸橼酸托法替尼 |
| 中文别名: | 枸橼酸托法替尼;2-甲基芴;Tofacitinib citrate(CP690550) 抑制剂;枸橼酸托法替布;柠檬酸托法替尼;托法替尼;托法替尼枸橼酸盐;托法替尼柠檬酸;托法替尼柠檬酸盐 |
| smiles: | O=C(C([H])([H])C#N)N1C([H])([H])C([H])([H])[C@@]([H])(C([H])([H])[H])[C@]([H])(C1([H])[H])N(C([H])([H])[H])C1C2C([H])=C([H])N([H])C=2N=C([H])N=1.O([H])C(C(=O)O[H])(C([H])([H])C(=O)O[H])C([H])([H])C(=O)O[H] |
| 英文名称: | Tofacitinib (CP-690550) Citrate |
| 英文别名: | Tofacitinib (Tasocitinib, CP-690550);Tofacitinib (CP-690550) Citrate;CP-690550 Citrate (Tofacitinib Citrate);1-PIPERIDINEPROPANENITRILE, 4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YLAMINO)-BETA-OXO-, (3R,4R)-, 2-HYDROXY-1,2...;CP 690,550;CP 690550 citrate;Tasocitinib citrate;Tasocitinib citric acid salt;tofacitinib;Tofacitinib citrate;Tofacitinib citrate(CP690550);TOFACITINIB, CITRATE SALT;Tofacititinib cirate;2-hydroxypropane-1,2,3-tricarboxylic acid,3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile;3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile 2-hydroxypropane-1,2,3-tricarboxylate;citro;CP-690,550-10;CP-690550 citrate;Xeljanz;(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-1-piperidinepropanenitrile citrate salt;3-[(3R,4R)-4-Methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile citrate salt;Tasocitinib citrate salt;CP 690500-10;CP 690550-10;Tofacitinib (citrate);O1FF4DIV0D;Tofacitinib citrate [USAN];Xeljanz Xr;citro; tofacitinib;3-{(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}-3;CP-690550-10 |
| CAS号: | 540737-29-9 |
| 分子式: | C22H28N6O8 |
| 分子量: | 504.49 |
| 密度: | |
| 熔点: | |
| 沸点: | |
| 闪点: | |
| 水溶性: | |
| 蒸气压: |
枸橼酸托法替尼
英文名:
Tofacitinib (CP-690550) Citrate
别名:枸橼酸托法替尼;2-甲基芴;Tofacitinib citrate(CP690550) 抑制剂;枸橼酸托法替布;柠檬酸托法替尼;托法替尼;托法替尼枸橼酸盐;托法替尼柠檬酸;托法替尼柠檬酸盐
商品编号:R023906-250mg
规格:250mg
纯度:99%
CAS号: 540737-29-9
分子式:C22H28N6O8
分子量:504.49
| 价格 |
¥ 6719.00
(请 登录 会员查看折扣价)
|
| 货期 | 5~7个工作日 |
数量
搜索质检报告(COA)
搜索MSDS
相关产品


















